Table 2.

Completed clinical trials assessing the safety and efficacy of MSC and MSC-derived extracellular vesicles therapy in ARDS secondary to COVID-19.

CT Title	Trial Phase	MSC Source	Patient Status	N	Route of Administration	Endpoints	Dose	Results	Reference n°
Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome	1–2	Allogeneic UC-MSC	COVID-19 ARDS	12	Intravenous	Adverse events Numbers of patients alive to day 28 Ventilator free days to day 28	25, 50 and up to 90 × 106 cell/unit dose	No study results posted	NCT04400032
Use of UC-MSC for COVID-19 Patients	1–2	Allogeneic UC-MSC	COVID-19 ARDS	24	Intravenous	Adverse events Survival rate after 90 days post first infusion Ventilator free days to day 28 Clinical Improvement	100 × 106 cells/infusion	No study results posted	NCT04355728
Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS (EXIT-COVID19)	2	Allogeneic BM-MSC	COVID-19 ARDS	120	Intravenous	Adverse Events All-cause mortality to day 61 Pa02/Fi02 ratio to day 61 Clinical, laboratory parameters and quality of life Improvement	800 billion and 1,2 trillion EV	No results posted	NCT04493242